Skip to content
Home
Our Team
Board of Directors
Management
Join Our Team
Academic Collaboration
Areas of Focus
Scientific Overview
Therapeutic Areas
Pipeline
Development Pipeline
AIV001
AIV007
JEL Technology
Investor & Media
Contact
Home
Our Team
Board of Directors
Management
Join Our Team
Academic Collaboration
Areas of Focus
Scientific Overview
Therapeutic Areas
Pipeline
Development Pipeline
AIV001
AIV007
JEL Technology
Investor & Media
Contact
×
Home
Our Team
Board of Directors
Management
Join Our Team
Academic Collaboration
Areas of Focus
Scientific Overview
Therapeutic Areas
Pipeline
Development Pipeline
AIV001
AIV007
JEL Technology
Investor & Media
Contact
Get the Latest News on Our Pharmaceutical Company
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
December 11, 2023
Learn More
AiViva BioPharma Appoints Les Kaplan, PhD, to the Board of Directors
December 7, 2023
Learn More
AiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors
August 30, 2023
Learn More
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
May 22, 2023
Learn More
AiViva BioPharma Announces New Patent Received
August 17, 2022
Learn More
AiViva BioPharma is recognized by Life Sciences Review as Top 20 Clinical-Stage Biopharmaceutical Company for 2022
May 24, 2022
Learn More
AiViva BioPharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer
October 2, 2020
Learn More
AiViva BioPharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
June 25, 2020
Learn More
Get AiViva Investor Brief
Search
Scroll To Top